HLX07
Phase 3Small molecule
Shanghai Henlius BiotechHLX07 is one of 53 small molecule programs targeting Phase II Clinical Study. It is currently in Phase 3.
3
Indications
12
Total Trials
3
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Anktiva
SSWOG Cancer Research Network
Phase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
HLX07
Shanghai Henlius BiotechPhase 3
Remeron
OOrganon and Co
Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase II Clinical Study2 trials
Gastric Cancer1 trial
Hepatocellular Carcinoma1 trial
Advanced or Metastatic Solid Tumors1 trial
6 more indications
Non-Small Cell Lung Cancer1 trial
Small Cell Lung Cancer1 trial
Cutaneous Squamous Cell Carcinoma1 trial
Head and Neck Tumors1 trial
Advanced Solid Cancers1 trial
Recurrent or Metastatic NPC1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HLX07. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company